Nuveen LLC Purchases Shares of 788,026 LivaNova PLC $LIVN

Key Points

• Nuveen LLC has acquired 788,026 shares of LivaNova PLC, valued at approximately $30.95 million, representing 1.45% ownership in the company.
• A large portion of LivaNova's stock, approximately 97.64%, is currently owned by institutional investors and hedge funds, indicating strong institutional interest in the company.
• LivaNova's latest earnings report showed 10.6% revenue growth year-over-year, with an earnings per share of $1.05, surpassing analyst expectations.

Nuveen LLC purchased a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 788,026 shares of the company's stock, valued at approximately $30,954,000. Nuveen LLC owned approximately 1.45% of LivaNova as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its position in LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after purchasing an additional 219 shares in the last quarter. Central Pacific Bank Trust Division increased its holdings in shares of LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after buying an additional 290 shares in the last quarter. CWM LLC increased its holdings in shares of LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after buying an additional 299 shares in the last quarter. Mariner LLC increased its holdings in shares of LivaNova by 8.4% during the fourth quarter. Mariner LLC now owns 5,741 shares of the company's stock worth $266,000 after buying an additional 446 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of LivaNova by 2.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company's stock worth $817,000 after buying an additional 500 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Trading Up 4.1%

LIVN stock traded up $2.19 during midday trading on Friday, reaching $55.05. The company's stock had a trading volume of 78,148 shares, compared to its average volume of 704,094. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $57.35. The stock has a market cap of $3.01 billion, a PE ratio of -14.17 and a beta of 0.92. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The business's 50-day simple moving average is $46.22 and its 200-day simple moving average is $43.02.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.21. The company had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the business posted $0.93 earnings per share. As a group, sell-side analysts expect that LivaNova PLC will post 2.85 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Barclays raised their price objective on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a report on Tuesday, May 20th. Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Robert W. Baird increased their price target on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.